CYduct Diagnostics Inc (OTCMKTS:CYDX) Stock In Focus After Recent News

Life enhancing breast healthcare development company CYduct Diagnostics Inc (OTCMKTS:CYDX) was in the news cycle yesterday after the company made a key announcement. The company announced that not too long ago the United States Senator Chris Murphy had recognized CYduct as the ‘Innovator of the Month’ for April.

Trading Data

On Thursday, CYDX stock ended flat at $0.7250 with more than 941 shares, compared to its average volume of 198 shares. The stock moved within a range of $0.7250 – 0.7250 after opening trading at $0.4600.

CYduct Diagnostics Recognized as April’s “Innovator of the Month” by U.S. Senator Chris Murphy

The company is currently working on the commercialization of the first proteomic test for breast cancer risk assessment of a personalized nature. The product that is being development is meant for testing for high risk biomarkers accurately so that the onset of breast cancer could recognized early.

More importantly, it would also help women, healthcare professionals and physicians in making the best possible decisions with regards to the treatment. The company is targeting only those groups of women who are at a high risk owing to denser breast tissue. The product is also expected to result in reducing the high number of false positives and false negatives in the risk assessment tests which are currently available.

The recognition from the Senator was an indication of the sort of innovative work that CYduct had been conducting over the course of the recent months. It may be a good time to keep an eye on it.